1 drug(s) with this reaction
271 total reports
Injection Site Swelling has been reported as an adverse reaction across 1 drug(s) manufactured by Amgen Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 271 adverse event reports mention injection site swelling in connection with Amgen Inc products.
This page provides a breakdown of which Amgen Inc drugs are most commonly associated with injection site swelling, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Amgen Inc drugs have injection site swelling listed in their FDA adverse event reports, sorted by report count:
In addition to injection site swelling, the following adverse reactions have been reported across Amgen Inc's drug portfolio:
1 drug(s) manufactured by Amgen Inc have injection site swelling listed in their FDA adverse event reports: ROMOSOZUMAB-AQQG.
There are a combined 271 reports of injection site swelling across 1 Amgen Inc drug(s) in the FDA adverse event database.